A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IRL 201104 (Primary)
Indications Adult respiratory distress syndrome; Eosinophilic oesophagitis; Seasonal allergic rhinitis
Focus Adverse reactions
Sponsors Revolo Biotherapeutics

21 Sep 2023 According to Revolo Biotherapeutics media release, company announced the completion of a Phase 1 multiple ascending dose (MAD) clinical trial evaluating the safety and tolerability of the companys immune-resetting drug candidate, IRL 201104, in healthy volunteers
21 Sep 2023 Results presented in the Revolo Biotherapeutics media release.
21 Sep 2023 Status changed from recruiting to completed, according to Revolo Biotherapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com